

## The nomination committee's proposal regarding election of board members of Bio-Works

The Nomination Committee for Bio-Works Technologies has resolved to submit the following proposal regarding election of the Board of Directors to the Annual General Meeting of Bio-Works on May 24, 2024.

- The Board of Directors shall consist of five members (four at present)
- Re-election of Peter Ehrenheim, Kirsti Gjellan, Johan Sedihn and Peter Nählstedt as Board members
- Election of Jonas Ahlén, CEO of Bonit Capital, as new member of the Board of Directors
- Re-election of Peter Ehrenheim as Chairman of the Board

The Nomination Committee resolved to propose PWC, with Niclas Bergenmo as auditor in charge, for the period until the next Annual General Meeting.

The Nomination Committee resolved to propose to the Annual General Meeting the following remuneration to the Board of Directors:

- Chairman Peter Ehrenheim shall receive remuneration of SEK 260,000
- The other members shall each receive remuneration of SEK 130,000
- No remuneration shall be paid for work in the committees of the Board of Directors

The Nomination Committee urged the Chairman to emphasize the importance of Board members and management combining Board work with ownership in the company in which they work. This, of course, provided that shares in Bio-Works are seen as a potentially good investment.

The Nomination Committee for the 2024 Annual General Meeting consists of:

- Staffan Persson represented Swedia Invest AB
- Erik Åfors represented Calyptra AB
- Dariush Hosseinian represented Karkas Capital AB
- Peter Ehrenheim, Chairman of the Board, Adjunct

Staffan Persson is Chairman of the Nomination Committee.

### Contacts

For more information, please visit the Bio-Works homepage at, [www.bio-works.com](http://www.bio-works.com) or contact: Arne Hauge, CFO, e-mail: [arne.hauge@bio-works.com](mailto:arne.hauge@bio-works.com), phone: +46(0)8-502 705 83.

**About Bio-Works**

Bio-Works enables scientists to achieve their purification goals, from laboratory research to large scale bioprocess production. Our vision is a biotech industry that embraces, develops and builds on new methods and novel ideas. WorkBeads™, Bio-Works' next-generation, agarose-based products, are used to purify proteins, peptides and other biomolecules, resulting in purer therapies and safer diagnostics. Through collaboration with customers and partners, we develop purification solutions that make important medicines available and accessible to everyone.

Bio-Works' headquarters, with R&D and manufacturing, is located in Uppsala Business Park in Uppsala, Sweden. We supply products globally, through a combination of direct sales and via distributors in Europe, North America and Asia. The company is certified according to the ISO 9001:2015 quality management system. Bio-Works is listed on Nasdaq First North ("BIOWKS"), and FNCA Sweden AB is appointed Certified Adviser. For more information, visit [www.bio-works.com](http://www.bio-works.com).

**Attachments**

[The nomination committee's proposal regarding election of board members of Bio-Works](#)